Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. presented preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting on November 7, 2026. APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation under immunosuppressive conditions; both combine CD40 activation with T-cell engagement. APVO711 combines CD40 activation with PD-L1 checkpoint blockade.
Aptevo says its molecules are designed to concentrate immune activation within the tumor microenvironment rather than broadly stimulating the immune system throughout the body. The company described the findings as supporting continued development of potential solid-tumor treatments.
Aptevo Therapeutics Inc. reported that successive refinements to mipletamig’s priming-dose regimen were associated with a substantial reduction in infusion-related reactions during initial treatment. Mipletamig is being evaluated with venetoclax and azacitidine in the RAINIER study.
The company expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase 2 development in 2027. Mipletamig data will be presented at the ASH 68th Annual Meeting from December 12–15, 2026. Aptevo said the findings do not establish improved efficacy or treatment persistence.
Aptevo Therapeutics Inc. (APVO) filed a prospectus supplement for offers and sales of its common stock from time to time, with an aggregate offering price of up to $2,309,834, under its existing agreement with Roth Capital Partners, LLC, as sales agent. The shares are offered under the company’s effective Form S-3 registration statement, and offerings will be made only by means of the prospectus.
As of the prospectus supplement, Aptevo had issued and sold 303,157 shares under the agreement and prior prospectuses for $11.8 million in aggregate gross sale proceeds. The supplement further amends and supplements those earlier prospectus materials.
Aptevo Therapeutics Inc. (APVO) may offer and sell additional common stock with an aggregate offering price of up to $2,309,834 from time to time through Roth Capital Partners as sales agent under its at-the-market agreement. The amount is subject to Form S-3’s limit of one-third of Public Float in any 12-month period while Public Float remains below $75,000,000.
Public Float as of October 30, 2026 was $6,929,502, based on 2,665,193 shares of common stock issued and outstanding and held by non-affiliates on that date, and a share price of $2.60 as of September 2, 2026. Aptevo reported 303,157 shares sold under the Sales Agreement and Prior Prospectus for aggregate gross sale proceeds of $11,799,276. It also reported $0 of securities sold under General Instruction I.B.6 during the prior 12-month period. If Public Float increases enough to permit a greater amount of sales, Aptevo says it will file another prospectus supplement before making those sales.
Aptevo Therapeutics Inc. reported that 10 of 47 evaluable frontline AML patients (21%) treated with mipletamig plus venetoclax and azacitidine advanced to allogeneic stem cell transplant. Nine patients were in the ongoing Phase 1b RAINIER trial and one was in a previously completed dose expansion trial; the patients were initially deemed unfit for intensive induction chemotherapy. The company describes transplant as a potentially curative option that can offer selected patients the possibility of long-term remission or cure.
For comparison, 3 of 286 patients (0.7%) receiving venetoclax and azacitidine in the VIALE-A trial subsequently underwent transplant. Aptevo cautioned that cross-trial comparisons are limited by differences in patient populations, study design and follow-up. It expects RAINIER dose optimization to conclude by year-end 2026, with FDA interaction and initiation of a Phase 2 trial anticipated in the first half of 2027.
Aptevo Therapeutics Inc. amended its Rights Agreement with Broadridge Corporate Issuer Solutions, LLC, as rights agent, on October 23, 2026. The amendment extends the defined “Final Expiration Date” to October 23, 2027, and changes the defined “Purchase Price” to $14.56 per one one-thousandth of a Series A Junior Participating Preferred Share, which has a par value of $0.001 per share.
Aptevo Therapeutics Inc. (APVO) announced it will present its multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting, scheduled for November 4–8, 2026, in Phoenix. The presentation, titled “Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity,” lists abstract number 1060 and presenter Michelle Nelson, PhD, et al.
Aptevo says the presentation will feature its CD40-directed portfolio and technology designed to combine tumor targeting with localized CD40 and T-cell activation, engaging innate and adaptive immunity in the tumor microenvironment while seeking to limit systemic immune activation. The company says a copy will be posted on its Publications page after the presentation.
Aptevo Therapeutics Inc. reported progress in its next-generation trispecific programs, optimizing several candidates for reliable, scalable manufacturing as a step toward future human testing. The company expects to enter Investigational New Drug (IND)-enabling studies for lead candidate APVO451 in the first half of 2027.
Aptevo describes trispecifics as molecules combining three functions to recognize cancer, activate immune cells and address tumor defenses. It says the manufacturing work may support additional trispecific candidates and expects to present further details at an upcoming international scientific conference. The stated development plans and timing are forward-looking statements.
Aptevo Therapeutics Inc. (APVO) reported results from its September 22, 2026 special meeting. Stockholders approved an issuance of more than 20% of the Company’s issued and outstanding common stock as of August 12, 2026 in connection with warrant reload and private placement transactions with certain holders. They also approved the Fifth Amended and Restated 2018 Stock Incentive Plan and authorization to adjourn the meeting if necessary or appropriate. A proposed certificate amendment making technical and administrative changes was not approved.
The certificate amendment received 654,005 votes for, 93,851 against, and 4,759 abstentions. The issuance proposal received 319,306 for, 100,098 against, and 4,225 abstentions; the plan received 331,590 for, 82,399 against, and 9,640 abstentions; and adjournment authorization received 639,823 for, 92,829 against, and 19,963 abstentions.
Aptevo Therapeutics Inc. (APVO) is registering up to 6,444,858 shares of common stock for resale by existing investors, all issuable upon the exercise of pre-funded warrants, common warrants and inducement warrants. These are secondary sales by selling stockholders; Aptevo will not receive proceeds from their resale.
As context, Aptevo had 1,810,215 shares outstanding as of August 21, 2026, so the registered warrant shares are large relative to current equity. The warrants generally cannot be exercised above 4.99% or 9.99% beneficial ownership caps. APVO remains listed on Nasdaq, with a reported share price of $2.60 on September 2, 2026, but discloses risks around equity dilution and potential future Nasdaq listing deficiencies, including stockholders’ equity, bid-price and market-value-of-listed-securities requirements.